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Time-of-Day Dictates 
Transcriptional Inflammatory 
Responses to Cytotoxic 
Chemotherapy
Jeremy C. Borniger, William H. Walker II, Monica M. Gaudier-Diaz, Curtis J. Stegman, 
Ning Zhang, Jennifer L. Hollyfield, Randy J. Nelson & A. Courtney DeVries
Many cytotoxic chemotherapeutics elicit a proinflammatory response which is often associated with 
chemotherapy-induced behavioral alterations. The immune system is under circadian influence; 
time-of-day may alter inflammatory responses to chemotherapeutics. We tested this hypothesis by 
administering cyclophosphamide and doxorubicin (Cyclo/Dox), a common treatment for breast cancer, 
to female BALB/c mice near the beginning of the light or dark phase. Mice were injected intravenously 
with Cyclo/Dox or the vehicle two hours after lights on (zeitgeber time (ZT2), or two hours after lights 
off (ZT14). Tissue was collected 1, 3, 9, and 24 hours later. Mice injected with Cyclo/Dox at ZT2 lost 
more body mass than mice injected at ZT14. Cyclo/Dox injected at ZT2 increased the expression 
of several pro-inflammatory genes within the spleen; this was not evident among mice treated at 
ZT14. Transcription of enzymes within the liver responsible for converting Cyclo/Dox into their toxic 
metabolites increased among mice injected at ZT2; furthermore, transcription of these enzymes 
correlated with splenic pro-inflammatory gene expression when treatment occurred at ZT2 but not 
ZT14. The pattern was reversed in the brain; pro-inflammatory gene expression increased among mice 
injected at ZT14. These data suggest that inflammatory responses to chemotherapy depend on time-of-
day and are tissue specific.
The toxicity of over 40 anticancer drugs, including cytostatics, cytokines, and targeted biological agents, is largely 
modified by circadian timing1. The DNA intercalator doxorubicin2 and the alkylator cyclophosphamide3 show 
marked circadian variation in toxicity and tolerability. In the case of doxorubicin, these circadian effects persist 
in constant darkness or constant light, eliminating the covariate of masking by darkness or light4. As circadian 
physiology between nocturnal rodents and diurnal humans is nearly 12 h out of phase, drug chronopharmacology 
typically displays opposite patterns between these species5.
Cancer chronotherapy depends on administration of treatment at times that coincide with optimal drug 
metabolism and effects on cell cycle progression, DNA repair, and apoptosis1. Additionally, several studies 
have demonstrated that peripherally administered cancer chemotherapeutics cause a peripheral and central 
inflammatory response6–10. Inflammatory cytokines (e.g., IL-1β , IL-6, and TNF-α ) display a circadian rhythm 
in production and secretion, peaking during the early inactive phase coinciding with sleep onset, although 
organ- and cell-type deviations exist11–14. Scheving and colleagues demonstrated a several-fold greater efficacy 
of doxorubicin-cyclophosphamide in male mice treated at ZT13 [zeitgeber time (ZT); 1 h into active phase] as 
compared to ZT1 (1 h into inactive phase); the mechanisms may relate to enhanced cytokines production at ZT1, 
that could then both disrupt the immune response of the host and accelerate cancer growth15.
It remains unknown whether inflammatory responses to chemotherapeutics are altered by the timing of drug 
administration throughout the day, and whether the inflammatory response is linked to ‘time-of-day dependent’ 
side effects of treatment. One recent study examined transcript changes in the liver of mice administered various 
doses of cyclophosphamide (Cyclo) during the mid-day and mid-night (ZT 8 and ZT 20)16. Genes involved in 
immune responses were significantly upregulated by cyclophosphamide only in the group that was administered the 
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drug during the light phase, suggesting that hepatic immune responses to cyclophosphamide are under circadian 
control. It is also unknown whether similar responses occur centrally, in other organs, or with different chemother-
apeutic regimens. We hypothesized that time-of-day influences inflammatory responses to cytotoxic chemo-
therapy. To test this hypothesis, we administered a cocktail of cyclophosphamide/doxorubicin (Cyclo/Dox; IV) 
at two different times of day (shortly after onset of light, and shortly after onset of dark) to female ovariectomized 
mice, and collected tissue/serum 1, 3, 9, and 24 hours later (experimental design: Fig. 1). We predicted that mice 
administered doxorubicin/cyclophosphamide chemotherapy at the beginning of their normally inactive phase 
(ZT 2) would display an exaggerated inflammatory response compared to mice injected at the beginning of their 
normally active phase (ZT 14).
Methods
Animals. Adult female BALB/c mice (> 8 wks; Charles River Laboratories, Wilmington, MA, USA) were used 
in the experiments described herein. All mice were allowed to acclimate to our facility for 1 wk after arrival, and 
then were ovariectomized to eliminate the covariate of acute ovarian failure in response to chemotherapy17,18. 
All surgeries were conducted using aseptic technique by an experienced surgeon (NZ), and mice were supplied 
analgesia (0.05 mg/kg buprenorphine, SC) and post-operative warmth (cage placement on a heating pad) until 
mobile. Ibuprofen (~30 mg/kg) was supplied in the drinking water for 5 days following surgery for further analge-
sia. Mice were group housed (4/cage) for 2 wks prior to experimental assignment. Mice were supplied ad libitum 
food (Harlan Teklad #7912) and filtered tap water, as well as a cotton nestlet. Cages were changed weekly. Mice 
were maintained on a 12:12 light/dark cycle. Body mass measures were obtained on the day prior to injection, and 
then at tissue collection 1, 3, 9, and 24 h post-injection. All experiments were approved and carried out in accord-
ance with guidelines set by The Ohio State University Institutional Animal Care and Use Committee (IACUC).
Agent Administration. At ZT 2 (2 h after lights ON) or ZT 14 (2 h after lights OFF), mice were brought 
into an adjacent procedure room, briefly restrained in a conical tube, and injected intravenously (tail vein) with a 
cocktail of 13.5 mg/kg doxorubicin and 135 mg/kg cyclophosphamide or saline vehicle as previously described10. 
This drug cocktail is commonly used as adjuvant treatment for localized breast cancer, as well for the treatment 
of metastatic disease19. Dosing was determined from 75% of the human equivalent dose based on a body surface 
area equation20. Injections at ZT 14 were completed under dim (< 5 lux) red light to prevent circadian disruption 
by short-wavelength light.
Tissue Collection. Mice were rapidly euthanized via cervical dislocation and decapitation 1, 3, 9, and 24 h 
after agent administration. Whole brain, spleen and liver were collected on ice into 1.5 mL polypropylene tubes 
containing RNA-Later Reagent (Qiagen), and subsequently stored at − 80 °C until RNA extraction or other down-
stream analyses. Whole blood was collected, centrifuged at 4000 × g for 25 min, and serum supernatant was 
subsequently stored at − 80 °C until assayed.
Cytokine Multiplex Assay. To examine cytokine and chemokine concentrations in serum, a multi-
plex inflammatory panel was conducted (V-Plex proinflammatory panel 1, Meso-Scale Discovery, Rockville, 
Maryland, USA) according to the manufacturer’s instructions. This kit measures protein levels of IFN-γ , IL-10, 
IL-12p70, IL-1β , IL-2, IL-4, IL-5, IL-6, KC/GRO (CXCL1), and TNF-α . A subset of the samples (111/128) had 
sufficient serum to be included in the multiplex assay; n ≥ 4/group/timepoint).
Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR). RNA was extracted using TriZol 
reagent (Life Technologies, Thermo Fisher Scientific Inc.) according to the manufacturer’s instructions. RNA 
pellets were resuspended in sterile, RNase-free water and quality and quantity were determined using a spectro-
photometer (NanoDrop, Thermo Fisher Scientific Inc.). cDNA was synthesized using M-MLV reverse transcrip-
tion. 20 ng of subsequent cDNA template was used in each qPCR reaction. Inventoried primer/probe pairs from 
Applied Biosystems (Life Technologies) were used (information available in Table 1). Probes that span exons were 
chosen to prevent amplification of residual gDNA. Taqman Fast Advanced Master Mix (Life Technologies) con-
taining AmpliTaq Fast DNA polymerase was used in a 20 μ L duplex reaction containing target primer/probes and 
one for the endogenous control eukaryotic 18 s rRNA. The 2-step RT-qPCR cycling conditions were: a holding 
stage of 95 °C for 20 s, 40 cycles of 95 °C for 3 s, and then 60 °C for 30 s. Relative gene expression was calculated 
using a relative standard curve, normalized to 18 s rRNA signal.
Figure 1. Experimental Design. Mice were intravenously injected with Cyclo/Dox or the vehicle at ZT 2 or ZT 
14. Tissue was collected 1, 3, 9, and 24 h later from each of these time points. Blue arrows denote the 24 h tissue 
collection time point.
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Corticosterone Enzyme Immunoassay (EIA). Serum corticosterone was determined using an enzyme 
immunoassay kit (DetectX, K014-H5, Arbor Assays, Michigan, USA). In brief, samples were diluted with dis-
sociation reagent and assay buffer 1:100, and assayed in duplicate. Plates were read on a plate reader at 450 nm, 
and concentrations were determined using a 4-parameter logistic curve plotting unknowns against standard 
corticosterone values. This assay was run after using a significant amount of serum for the multiplex cytokine 
analyses described above, and therefore not all samples contained sufficient serum to be assayed for corticoster-
one (77/128). Therefore, the results presented provide only a snapshot of corticosterone concentrations at 24 h 
post-injection. The average intra-assay coefficient of variation was 8.17% and the inter-assay %CV was 7%.
Statistical Analyses. Factorial ANOVAs with treatment, injection time, and time after injection as fixed 
factors were used. To control for circadian variation in gene expression, data were analyzed (and displayed) as 
fold change from time-matched vehicle controls. When significant F values were detected, post-hoc univariate 
ANOVAs were completed to examine time-point specific differences between groups. Data that did not show 
equal variance were subjected to non-parametric tests (i.e., Mann-Whitney U). Percent change in body mass 
measures from baseline between each group was compared using a paired-samples t-test. Values for each variable 
that fell ≥ 2 standard deviations outside of the group mean (Z-score) were considered outliers and removed from 
analyses a priori. For the spleen, liver, hypothalamus, and hippocampus, 3, 7, 4, and 4 samples (respectively) failed 
to amplify during PCR, and their data were therefore not analyzed. Outliers were determined within each experi-
mental group (that is, split by time of injection (ZT 2 vs. 14), injection type (chemo vs. veh), and tissue collection 
time point (1, 3, 9, and 24 h later) resulting in 16 groups that were independently tested for aberrant values in 
each measure. After this, each group had between 6–8 animals for the spleen, 5–8 animals for the liver, and 5–8 
animals for the brain per gene analyzed; no more than 1 animal/timepoint/treatment was excluded by Z-score 
analysis. Final sample sizes are listed in the figure legends. Body mass for one mouse was not recorded prior to 
sample collection and is therefore not included in the analysis. All statistics were completed using SPSS Statistics 
version 23 (IBM, Armonk, NY) and GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). Mean differences 
were considered statistically significant when p ≤ 0.05.
Results
Time of Injection Alters Body Mass Loss After Cyclo/Dox Administration. Due to normal circa-
dian variation in food intake and activity that can affect body mass, analyses were conducted on percent change 
in body mass from baseline. 24 h after agent administration, ZT 2 treated animals lost significantly more weight 
(− 5.603 ± 2.85%) than their counterparts injected at ZT 14 (− 2.02 ± 2.48%; t = 3.147, p = 0.016) compared to 
their time-matched vehicle controls (Fig. 2).
Injection Time Alters Splenic Cytokine Transcription. Cytokine transcription was measured in the 
spleen as an index of the peripheral immune response (Fig. 3). Chemo-treated animals increased gene expression 
of splenic IL-1β (F1,95 = 46.005, p < 0.0001), IL-6 (F1,97 = 11.97, p < 0.001), TNF-α (F1,101 = 22.551, p < 0.0001), 
SOCS3 (F1,101 = 32.86, p < 0.0001), IL-1ra (F1,100 = 22.164, p < 0.0001), iNOS (F1,98 = 6.243, p < 0.05), but not 
MAC-1 (aka ITGAM) (F1,98 = 1.461, p > 0.05). There was an interaction between injection time and treatment 
in IL-1β (F1,95 = 10.689, p < 0.005), TNF-α (F1,101 = 6.917, p < 0.01), SOCS3 (F1,101 = 11.6, p < 0.001), IL-1ra 
(F1,100 = 10.523, p < 0.005), iNOS (F1,98 = 10.539, p < 0.005), but not IL-6 (F1,97 = 1.308, p > 0.05) or MAC-1 
(F1,98 = 1.293, p > 0.05) expression, such that animals injected at ZT 2 displayed elevated responses to chemo-
therapy injection compared to animals injected at ZT 14. Corticosterone concentrations were altered by injection 
time and treatment 24 h post-injection (F3,21 = 3.9, p < 0.05); corticosterone was elevated at ZT 14 compared to 
ZT 2 in vehicle-treated mice (Tukey HSD post-hoc; p < 0.05), and chemotherapy treatment increased circulating 
corticosterone concentrations in mice injected at ZT 2 (p < 0.05), but not ZT 14 (p > 0.05) (Fig. 3i). These data 
suggest that injection time has differential effects on the glucocorticoid response to chemotherapy treatment.
Gene Assay ID Amplicon Size (bp)
Il6 Mm00446190_m1 78
Il1b Mm00434228_m1 90
Socs3 Mm01249143_g1 113
Tnf Mm00443258_m1 81
Il1rn Mm00446186_m1 80
Cbr1 Mm04207333_g1 83
Cyp2b10 Mm00456588_mH 88
Cyp3a13 Mm00484110_m1 88
Itgam Mm00434455_m1 69
Stat3 Mm01219775_m1 75
Nos2 (iNos) Mm00440502_m1 66
Ccl2 Mm00441242_m1 74
18s Hs99999901_s1 187
Table 1.  Primer/probe information for targets used in qPCR.
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Time of Injection Alters Central Cytokine Transcription. Central cytokine transcription was examined 
in the hypothalamus and hippocampus (Fig. 4). Chemotherapy increased hypothalamic IL-1β (F1,91 = 16.926, 
p < 0.0001), TNF-α (F1,92 = 11.591, p < 0.001), SOCS3 (F1,91 = 6.554, p < 0.05), STAT3 (F1,95 = 7.245, p < 0.01), 
IL-6 (F1,85 = 4.810, p < 0.05), and CCL2 (F1,93 = 22.336, p < 0.0001) expression. There also was an interaction 
between injection time and treatment in IL-1β (F1,91 = 11.469, p < 0.002), TNF-α (F1,92 = 8.16, p < 0.006), CCL2 
(F1,93 = 18.846, p < 0.0001), SOCS3 (F1,91 = 7.087, p < 0.01), and STAT3 (F1,95 = 4.978, p < 0.05) expression, such 
that mice injected at ZT 14 displayed elevated responses to chemotherapy injection compared to animals injected 
at ZT 2. This interaction was not observed in hypothalamic IL-6. This expression profile is nearly the opposite 
pattern to that observed in the spleen (Fig. 3).
Chemotherapy did not affect IL-1β expression within the hippocampus (F1,90 = 0.548, p > 0.05). However, 
there was an interaction among treatment, injection time, and time after injection (F3,90 = 5.422, p < 0.005), such 
that mice injected at ZT 14 showing an increase in expression at 9 h after injection that was not evident in mice 
injected at ZT 2 (Fig. 4h). Similar results were obtained for hippocampal TNF-α , with no main effect of treat-
ment evident (F1,90 = 0.063, p > 0.05), but an interaction between treatment and injection time (F1,90 = 10.954, 
p < 0.002), and an interaction among treatment, injection time, and hours after injection (F3,90 = 3.323, p < 0.05); 
i.e., animals injected at ZT 14 displayed increased hippocampal TNF-α 3 and 9 h post-injection (Fig. 4i).
Time of Injection Alters the Transcription of Enzymes Involved in Cyclo/Dox Metabolism. The 
expression of Cytochrome p450 genes Cyp2b10 and Cyp3a13 as well as carbonyl reductase (Cbr1) were examined 
in the liver (Fig. 5). Chemotherapy significantly increased expression of Cyp2b10 (F1,93 = 25.666, p < 0.0001), 
Cyp3a13 (F1,90 = 12.035, p < 0.001), and Cbr1 (F1,95 = 7.131, p < 0.01) in the liver compared to vehicle injec-
tion. There also was an interaction between treatment and injection time in Cyp2b10 expression (F1,93 = 8.565, 
p < 0.005), an effect not evident in Cyp3a13 (p > 0.05) or Cbr1 (p > 0.05) expression. The activity of Cyp2a10 pos-
itively correlated with the splenic expression of many proinflammatory cytokines in mice that were injected at ZT 
2 (IL-6: R = 3.26, p < 0.05; IL-1β : R = 0.579, p < 0.0001; SOCS3: R = 0.314, p < 0.05; TNF-α : R = 0.387, p < 0.01; 
IL-1ra: R = 0.348, p < 0.05), but not in mice injected at ZT 14 (except IL-1β : R = 0.3, p < 0.05) (Fig. 6a–c). A 
similar pattern was observed for Cyp3a13 (ZT 2: iNOS: R = 0.418, p < 0.01; SOCS3: R = 0.295, p < 0.05; TNF-α : 
R = 0.396, p < 0.01; IL-1ra: R = 0.353, p < 0.05; ZT 14: all correlations p > 0.05), but not for Cbr1 (excepting ZT 2 
iNOS: R = 0.295, p < 0.05; ZT 14: All genes p > 0.05). Liver transcription of these enzymes was related in a similar 
fashion to hypothalamic cytokine transcription, with Cyp2b10 correlating with several genes in mice injected at 
ZT 2 (Fig. 6d–f) (IL-1β : R = 0.346, p < 0.05; IL-6: R = 0.323, p < 0.05; STAT3: R = 0.318, p < 0.05; CCL2: R = 0.29, 
Figure 2. Time-of-day influences body mass loss following doxorubicin/cyclophosphamide 
administration. (a) Change in body mass after injection at ZT 2, and (b) ZT 14. (c) % change in body mass 
from time-matched vehicle treated mice at 24 h post-injection in animals injected at ZT 2 and ZT 14. ((N = 7–8/
group/timepoint) Error bars represent SEM. *p < 0.05)).
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p < 0.05), but not ZT 14 (p > 0.05 in all gene examined). Cyp3a13 transcription was associated with hypothalamic 
IL-6 expression in mice injected at ZT 2 (R = 0.401, p < 0.01), but not ZT 14 (p > 0.05 for all genes examined). 
Likewise, liver Cbr1 was positively correlated with hypothalamic IL-6 only in mice injected at ZT 2 (R = 0.34, 
p < 0.05; ZT 14: all genes examined p > 0.05).
Time of Injection Does Not Alter Circulating Cytokine Levels. There was a significant increase in 
serum IL-6 (F1,94 = 38.485, p < 0.0001) and CXCL1 (aka KC/GRO) (F1,98 = 19.19, p < 0.0001) concentrations, but 
not IFN-γ , IL-10, IL-1β , IL-2, IL-5, or TNF-α (p > 0.05 in all cases), among chemo-treated mice compared to 
vehicle-treated mice. There was no interaction between injection time and treatment in any of the serum proteins 
examined (p > 0.05 in all cases) (Fig. 7).
Discussion
Together, the data presented here demonstrate tissue-specific, time-of-day-dependent changes in inflammatory 
responses to cytotoxic chemotherapy. Mice injected with Cyclo/Dox at ZT 2 exhibited no increase in hypotha-
lamic IL-1β , TNF-α , IL-6, CCL2, STAT3, or SOCS3, a downstream target of JAK/STAT signaling, compared to 
vehicle treated animals. Animals treated at ZT 14, however, showed a biphasic expression of these genes in the 
hypothalamus, with peaks at 3 and 24 h after injection (Fig. 4). This pattern was similar in the hippocampus, 
where animals injected at ZT 14 increased hippocampal IL-1β and TNF-α 3–9 h following injection, a pattern 
not evident in mice injected at ZT 2 (Fig. 4h,i). The induction of inflammatory mediators within the brain dis-
played the opposite pattern from the spleen (Fig. 4). This difference between peripheral and central inflammatory 
Figure 3. Time-of-day alters splenic cytokine expression in response to IV cyclophosphamide and 
doxorubicin. (a–d) Expression of the inflammatory cytokines IL-6, Il-1β , TNF-α , and iNOS were enhanced 
in mice receiving Cyclo/Dox at ZT 2 compared to those administered the same dose at ZT 14. (e) By contrast, 
expression of MAC-1 was unchanged. (f,g) Anti-inflammatory pathway transcripts (SOCS3 and IL-1ra) were 
simultaneously enhanced in mice administered Cyclo/Dox at ZT 2 compared to ZT 14. (h) Average gene 
expression values across the entire post-injection time frame, (i) serum corticosterone concentrations 24 
following injection (N = 3–8/group; different letters denote statistical significance p < 0.05; Tukey HSD post-
hoc test). (N = 6–8/group/timepoint for gene expression data; error bars represent S.E.M. *p < 0.05, **p < 0.01, 
***p < 0.001 in relation to the time-matched vehicle control). The dotted line at y = 1 represents normalized 
vehicle values.
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signaling in response to chemotherapy may depend on clock gene activity within brain microglia and peripheral 
macrophages, which contain autonomous clocks that are 6–8 h out of phase with each other12,21. Additionally, 
central clocks and those in peripheral organs are ~4 h out of phase, reflecting the master/slave oscillator relation-
ship between them22,23. These data also highlight the notion that peripheral responses to an immune challenge 
cannot be considered a reliable indicator of the central response (e.g., see ref. 24). Results such as these provide 
additional evidence for the pleiotropic effects of cytokines, dependent on time-of-day and tissue specificity.
There also appears to be temporal variation in the activation of metabolic pathways of cyclophosphamide 
and doxorubicin. Cyclophosphamide is a prodrug that requires metabolic activation. Cyp2b10 is responsible 
for the conversion of cyclophosphamide into a toxic metabolite, 4-hydroxycyclophosphamide (4-OH), whereas 
Cyp3a13 contributes to both activation and inactivation of cyclophosphamide through conversion to 4-OH and 
the inactive compound dechloroethylcyclophosphamide (DCE; Fig. 5). The activity of these enzymes signifi-
cantly contributes to the toxicity of cyclophosphamide, and influences its tolerability. In the present study, mice 
injected at ZT 2 had increased Cyp2b10 gene expression (Fig. 5),which may suggest increased production of 
toxic 4-hydroxycyclophosphamide (4-OH) relative to mice treated at ZT 14. Consistent with this observation, a 
previous study reported increased mortality among mice treated with cyclophosphamide between ZT 22 and ZT 
2 relative to mice treated between ZT 10 and ZT143. This study, as well as a more recent one16, reported no tem-
poral effects on cyclophosphamide metabolism, however, these studies did not examine enzyme activity or serum 
metabolite concentration later than 4 hours after injection, while in the present study, the temporal effect on the 
metabolic pathway did not emerge until > 9 hours after injection (Fig. 5). We also observed a time-of-day effect in 
doxorubicin (DOX) metabolism. An initial step in DOX metabolism is its reduction to doxorubicinol (DOX-OL). 
DOX-OL is a less effective anti-neoplastic agent, and displays a greater capacity to induce cardiotoxicity. This 
initial conversion of DOX→ DOX-OL is catalyzed by carbonyl reductase I (Cbr1), primarily in the liver25. Mice 
that received chemo at ZT 2 elevated Cbr1 transcription at 24 h after injection compared to mice that received 
Figure 4. Time-of-day alters brain cytokine/chemokine expression in response to cytotoxic chemotherapy. 
Animals injected at ZT 14 displayed elevated hypothalamic (a) IL-1β , (B) TNF-α , (c) IL-6, (d) STAT3, (e) 
SOCS3, and (f) CCL2 expression over time in response to chemotherapy compared their counterparts injected 
at ZT 2 (g) Average hypothalamic values across the entire post-injection timeframe. (h) Hippocampal IL-1β and 
(i) TNF-α expression. (n = 5–8/group/timepoint; *p < 0.05, **p < 0.01 in relation to the time-matched vehicle 
control; Error bars represent S.E.M). The dotted line at y = 1 represents normalized vehicle values.
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treatment at ZT 14 (Fig. 5a). Taken together, the data suggest that enhanced inflammation in mice injected at ZT 
2 may reflect increased production of toxic drug metabolites 4-OH and DOX-OL. In support of this explanation, 
splenic inflammation was positively correlated with liver enzyme activity only in the mice administered Cyclo/
Dox at ZT 2, but not ZT 14 (Fig. 6). This ZT 2 specific correlation was also observed within the hypothalamus 
(Fig. 6d–f), even though inflammation in this tissue was enhanced in mice injected at ZT 14 relative to ZT 2, 
indicating that liver metabolism of Cyclo/Dox may be uncoupled from inflammatory processes occurring in the 
brain. Together, these data support the hypothesis that time-of-day dependent effects of administration likely 
depend on downstream cyclophosphamide actions on the DNA damage response, inflammation, or additional 
pathways16.
A potential contributor to the phenotype we observed could be sleep disruption. We have previously reported 
marked sleep fragmentation after administration of the same chemo regimen used in the present study10. As sleep 
disruption elicits an inflammatory response26,27, this may have contributed to the enhanced splenic inflammation 
observed in animals injected at ZT 2. Additionally, glucocorticoid concentrations peak during the early active 
phase in nocturnal rodents28, and they are negative regulators of inflammation, acting through multiple mecha-
nisms29,30. Therefore, elevated baseline concentrations of glucocorticoids in mice injected at ZT 14 may have con-
tributed to the dampened inflammatory response observed in the spleen, a pattern observed in the present study 
(Fig. 3i). Indeed, morning administration of doxorubicin and evening administration of cisplatin is much better 
Figure 5. Time-of-day alters the transcriptional activity of enzymes involved in cyclo/dox metabolism.  
(a) Carbonyl reductase (Cbr1) showed differential expression following chemotherapy injection at ZT 2 or ZT 
14. (b) this enzyme is responsible for the conversion of doxorubicin into a more toxic metabolite, doxorubicinol 
(DOX-OL). (c) Cyp2b10 was markedly elevated after ZT 2 injection, a pattern not evident after ZT 14 
injection, (d) Cyp3a13 also showed a similar induction pattern dependent on time-of-day, (e) The prodrug 
cyclophosphamide is converted into a toxic metabolite (4-OH) via Cyp2b10 and cyp3a13. Alternatively, it 
is converted into an inactive product by cyp3a13 (DCE). (n = 5–8/group/timepoint; *p < 0.05, **p < 0.01 in 
relation to the time-matched vehicle control; Error bars represent S.E.M.) The dotted line at y = 1 represents 
normalized vehicle values.
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tolerated than the opposite administration schedule in humans with advanced ovarian cancer31; it is hypothesized 
that peak glucocorticoid concentrations at the time of doxorubicin administration may buffer the inflammatory 
response to the drug.
Periphery-to-brain inflammatory signaling can be accomplished through several mechanisms32. Because we 
did not observe a change in serum cytokine responses to chemotherapy dependent on time-of-day (Fig. 7), it is 
unlikely that humoral signaling is the primary means by which chemotherapy elicits differential hypothalamic 
effects at ZT 2 and ZT 14. Alternatively, transcription of the monocyte recruiting chemokine CCL2 in the hypo-
thalamus was elevated following administration of chemotherapy at ZT 14, but not ZT 2 (Fig. 4f). Recently, 
direct interactions among the circadian clock and CCL2 have been reported to mediate time-of-day dependent 
responses to peripheral endotoxin administration, with peak hypothalamic CCL2 expression during the dark 
Figure 6. Splenic and hypothalamic inflammatory responses to chemotherapy are related to liver enzyme 
transcription only in mice injected at ZT 2. Pearson correlations between liver enzymes that metabolize 
cyclophosphamide: Cyp2b10, Cyp3a13 and splenic (a,b) and hypothalamic (d,e) inflammatory mediators. Cbr1, 
responsible for doxorubicin metabolism and its relation to splenic (c) and hypothalamic (f) inflammatory gene 
transcription after chemotherapy at ZT 2 or ZT 14. (*p < 0.05, **p < 0.01).
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(inactive) phase33. Therefore, the phenotype we observed within the hypothalamus may be driven by time-of-day 
dependent recruitment of peripheral monocytes/macrophages into the brain.
Several intriguing questions remain regarding the interactions among chemotherapy and other cancer- and 
treatment-related factors. For example, we chose to begin this line of inquiry by examining the effects of chemo-
therapy in non-tumor bearing mice because cyclophosphamide and doxorubicin combination therapy is typically 
given in an adjuvant setting once the tumor has been resected19. However, additional studies are necessary to 
determine whether a prior or current tumor sensitizes or causes a temporal shift in inflammatory responses to 
doxorubicin and cyclophosphamide. Comparing responses in mice that are tumor-naïve, tumor-bearing, versus 
tumor-resected will be critical for assessing whether tumors and/or the surgery associated with their removal 
prime inflammatory responses to chemotherapy and if so, how long after tumor removal the effects persist. 
Indeed, the primary reason the current study was conducted in BALB/C mice is that there are well-characterized 
metastatic and non-metastatic mammary tumor cell lines that are specific to this mouse strain (e.g., 4T1, 67NR, 
4T07). Despite muted nightly melatonin rhythms34, BALB/C mice display robust rhythms in immune cell activity, 
cytokine secretion, and response to endotoxin challenge. For instance, BALB/C mice display robust time-of-day 
dependent changes in LPS-responsiveness dependent on diurnal variations in NF-κ B activity35. Additionally, 
circadian sensitivity to cyclophosphamide has been demonstrated in C57BL/6j mice, which also lack robust 
circadian rhythms in melatonin production and secretion3,34, suggesting that a robust melatonin signal is not 
required for the time-of-day dependent effects of cyclophosphamide. Regardless, further studies should investi-
gate a potential role for endogenous melatonin in buffering inflammatory responses to cytotoxic chemotherapy.
The predictive value of rodent studies for human inflammatory conditions also has become a topic of debate 
recently36–38. How closely the liver, spleen, and brain inflammatory gene expression data collected in mice in the 
current study reflect changes occurring in human cancer patients is not ethically determinable with currently 
available technology. However, our data demonstrate that the potential exists for circadian differences in inflam-
matory and metabolic responses to a common chemotherapy regimen, and also that it should not be assumed that 
Figure 7. Serum (a) IL-6 and (b) CXCL1 concentrations were elevated in response to chemotherapy 
independent of time-of-day. (c) IL-2, (d) IL-5, (e) IL-1β , (f) IL-10, (g) IFN-γ , and (h) TNF-α were unchanged 
in response to treatment. (i) Average values between ZT 2 and ZT 14-injected animals over the entire post-
injection time frame. (N = 4–8/group/timepoint; Error bars represent S.E.M., *p < 0.05, **p < 0.01 compared to 
the time-matched vehicle average) (the dotted line at y = 1 represents normalized vehicle values).
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all tissues respond similarly. Nonetheless, the temporal aspects of chemotherapy treatment in patients with breast 
cancer is worth exploring given that there is a growing literature demonstrating diurnal variation in immune 
parameters associated with inflammatory diseases and experimental endotoxin exposure in people39,40.
In sum, our data demonstrate time-of-day-dependent changes in inflammatory responses to cytotoxic chemo-
therapy. Specifically, splenic inflammatory responses to cyclophosphamide and doxorubicin are maximal when 
the drugs are administered during the early inactive phase (ZT 2), and lowest when administered during the 
early active phase (ZT 14). By contrast, inflammatory gene expression within the hypothalamus displays the 
reciprocal pattern, as mice injected at ZT 14 show an enhanced hypothalamic inflammatory response compared 
to those injected at ZT 2. Additionally, the activity of enzymes responsible for the conversion of doxorubicin and 
cyclophosphamide into their toxic metabolites displays differential induction dependent on time-of-day, and 
their activity correlates with splenic and hypothalamic inflammatory responses only in mice injected during the 
early inactive phase. These data further add to the growing literature on cancer ‘chronotherapy’, and highlight 
inflammatory responses to treatment as a proximate cause of chemotherapy-induced side effects dependent on 
time of drug administration.
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